Back

Precision-cut liver slices as a model for the evaluation of host-targeting agents against hepatitis B and delta viruses

Roca Suarez, A. A.; Michelet, M.; Dubois, A.; Diederichs, A.; Plissonnier, M.-L.; Heintz, S.; Saez-Palma, M.; Fletcher, S. P.; Rivoire, M.; Phillips, S.; Palma, E.; Chokshi, S.; Zoulim, F.; Testoni, B.

2025-12-06 microbiology
10.64898/2025.12.06.692712 bioRxiv
Show abstract

Developing new therapeutic strategies against hepatitis B virus (HBV) and hepatitis delta virus (HDV) is essential to cure these infections. Yet evaluation of host-targeting agents (HTAs) with in vitro and in vivo models remains challenging. Therefore, we assessed precision-cut liver slices (PCLS) as an HBV/HDV co-infection model to study virus-host interactions and HTAs. Our ex vivo PCLS infection protocol allows to establish HBV and HDV infection within the livers three-dimensional architecture. Treatment with two well-characterized HTAs produced distinct antiviral effects consistent with each mechanism: Bulevirtide blocked entry; Lonafarnib induced intracellular hepatitis delta antigen accumulation. The TLR8 agonist Selgantolimod showed anti-HBV activity not previously seen in cultured hepatocytes, indicating crosstalk between immune and infected cells within PCLS. These results provide the first characterization of PCLS as an ex vivo model of HBV/HDV co-infection and antiviral testing. Thus, PCLS could expedite pre-clinical HTA characterization against viral liver diseases while reducing animal experimentation.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.